Association between CCND1 and XPC polymorphisms and bladder cancer risk: A meta-analysis based on 15 case-control studies

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3155-3165

  Wang, Yifei ^a   Li, Zongping ^b   Liu, Naibo ^a   Zhang, Guan ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^b Equipment Academy of Air Force   (China)

Author keywords

Bladder cancer; CCND1; Meta analysis; Polymorphism; XPC

Indexed keywords

CYCLIN D1;

ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CAUCASIAN; EMBASE; ETHNICITY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MEDLINE; PRIORITY JOURNAL; SMOKING; XERODERMA PIGMENTOSUM;

CASE-CONTROL STUDIES; CYCLIN D1; DNA-BINDING PROTEINS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, GENETIC; PUBLICATION BIAS; RISK; URINARY BLADDER NEOPLASMS;

EID: 84898873263     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1412-9     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Actinomycin C. Cumulative index to IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. IARC Monogr Eval Carcinog Risk Chem Hum. 1986;39:379-403.
3. Murta-Nascimento C, Schmitz-Drager BJ, Zeegers MP, Steineck G, Kogevinas M, et al. Epidemiology of urinary bladder cancer: from tumor development to patient's death. World J Urol. 2007;25:285-95.
4. Vineis P, Talaska G, Malaveille C, Bartsch H, Martone T, et al. DNA adducts in urothelial cells: relationship with biomarkers of exposure to arylamines and polycyclic aromatic hydrocarbons from tobacco smoke. Int J Cancer. 1996;65:314-6.
5. Turesky RJ, Freeman JP, Holland RD, Nestorick DM, Miller DW, et al. Identification of aminobiphenyl derivatives in commercial hair dyes. Chem Res Toxicol. 2003;16:1162-73.
6. Burger MS, Torino JL, Swaminathan S. DNA damage in human transitional cell carcinoma cells after exposure to the proximate metabolite of the bladder carcinogen 4-aminobiphenyl. Environ Mol Mutagen. 2001;38:1-11.
7. Siraki AG, Chan TS, Galati G, Teng S, O'Brien PJ. N-oxidation of aromatic amines by intracellular oxidases. Drug Metab Rev. 2002;34:549-64.
8. Wei Q, Spitz MR. The role of DNA repair capacity in susceptibility to lung cancer: a review. Cancer Metastasis Rev. 1997;16:295-307.
9. Kaufmann WK, Paules RS. DNA damage and cell cycle checkpoints. FASEB J. 1996;10:238-47.
10. Ronen A, Glickman BW. Human DNA repair genes. Environ Mol Mutagen. 2001;37:241-83.
11. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science. 2001;291:1284-9.
12. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer. 2001;1:22-33.
13. Tauchi H, Kobayashi J, Morishima K, van Gent DC, Shiraishi T, et al. Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells. Nature. 2002;420:93-8.
14. Matullo G, Guarrera S, Carturan S, Peluso M, Malaveille C, et al. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer. 2001;92:562-7.
15. Wang M, Gu D, Zhang Z, Zhou J. XPD polymorphisms, cigarette smoking, and bladder cancer risk: a meta-analysis. J Toxicol Environ Health A. 2009;72:698-705.
16. Li C, Jiang Z, Liu X. XPD Lys(751)Gln and Asp (312)Asn polymorphisms and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2010;37:301-9.
17. Sun H, Qiao Y, Zhang X, Xu L, Jia X, et al. XRCC3 Thr241Met polymorphism with lung cancer and bladder cancer: a meta-analysis. Cancer Sci. 2010;101:1777-82.
18. Li F, Li C, Jiang Z, Ma N, Gao X. XRCC3 T241M polymorphism and bladder cancer risk: a meta-analysis. Urology. 2011;77(511):e1-5.
19. Zhang Y, Wang X, Zhang W, Gong S. An association between XPC Lys939Gln polymorphism and the risk of bladder cancer: a meta-analysis. Tumour Biol. 2013;34:973-82.
20. Dou K, Xu Q, Han X. The association between XPC Lys939Gln gene polymorphism and urinary bladder cancer susceptibility: a systematic review and meta-analysis. Diagn Pathol. 2013;8:112.
21. Liu C, Yin Q, Li L, Zhuang YZ, Zu X, et al. APE1 Asp148Glu gene polymorphism and bladder cancer risk: a meta-analysis. Mol Biol Rep. 2013;40:171-6.
22. Zhang F, Wu JH, Zhao W, Liu HT. XRCC1 polymorphisms increase bladder cancer risk in Asians: a meta-analysis. Tumour Biol. 2013
23. Wang C, Sun Y, Han R. XRCC1 genetic polymorphisms and bladder cancer susceptibility: a meta-analysis. Urology. 2008;72:869-72.
24. Lao T, Gu W, Huang Q. A meta-analysis on XRCC1 R399Q and R194W polymorphisms, smoking and bladder cancer risk. Mutagenesis. 2008;23:523-32.
25. Lee CC, Yamamoto S, Morimura K, Wanibuchi H, Nishisaka N, et al. Significance of cyclin D1 overexpression in transitional cell carcinomas of the urinary bladder and its correlation with histopathologic features. Cancer. 1997;79:780-9.
26. Hosokawa Y, Arnold A. Mechanism of cyclin d1 (CCND1, PRAD1) overexpression in human cancer cells: analysis of allele-specific expression. Genes Chromosomes Cancer. 1998;22:66-71.
27. Zhou P, Jiang W, Weghorst CM, Weinstein IB. Overexpression of cyclin D1 enhances gene amplification. Cancer Res. 1996;56:36-9.
28. Sugasawa K, Shimizu Y, Iwai S, Hanaoka F. A molecular mechanism for DNA damage recognition by the xeroderma pigmentosum group C protein complex. DNA Repair (Amst). 2002;1:95-107.
29. Wang L, Habuchi T, Takahashi T, Mitsumori K, Kamoto T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257-64.
30. Chung CJ, Huang CJ, Pu YS, Su CT, Huang YK, et al. Polymorphisms in cell cycle regulatory genes, urinary arsenic profile and urothelial carcinoma. Toxicol Appl Pharmacol. 2008;232:203-9.
31. Lin HH, Ke HL, Hsiao KH, Tsai CW, Wu WJ, et al. Potential role of CCND1 G870A genotype as a predictor for urothelial carcinoma susceptibility and muscle-invasiveness in Taiwan. Chin J Physiol. 2011;54:196-202.
32. Garcia-Closas M, Malats N, Real FX, Welch R, Kogevinas M, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536-42.
33. Liu Y, Wang H, Lin T, Wei Q, Zhi Y, et al. Interactions between cigarette smoking and XPC-PAT genetic polymorphism enhance bladder cancer risk. Oncol Rep. 2012;28:337-45.
34. da Costa BR, Cevallos M, Altman DG, Rutjes AW, Egger M. Uses and misuses of the strobe statement: bibliographic study. BMJ Open. 2011;1:e000048.
35. Woolf B. On estimating the relation between blood group and disease. Ann Hum Genet. 1955;19:251-3.
36. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med. 2012;31:3805-20.
37. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295:676-80.
38. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2005;28:123-37.
39. Cortessis VK, Siegmund K, Xue S, Ross RK, Yu MC. A case-control study of cyclin D1 CCND1 870A → G polymorphism and bladder cancer. Carcinogenesis. 2003;24:1645-50.
40. Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729-34.
41. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis. 2005;26:1263-71.
42. Sak SC, Barrett JH, Paul AB, Bishop DT, Kiltie AE. Comprehensive analysis of 22 XPC polymorphisms and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:2537-41.
43. Wu X, Gu J, Grossman HB, Amos CI, Etzel C, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006;78:464-79.
44. Zhu Y, Lai M, Yang H, Lin J, Huang M, et al. Genotypes, haplotypes and diplotypes of XPC and risk of bladder cancer. Carcinogenesis. 2007;28:698-703.
45. Ye Y, Yang H, Grossman HB, Dinney C, Wu X, et al. Genetic variants in cell cycle control pathway confer susceptibility to bladder cancer. Cancer. 2008;112:2467-74.
46. de Verdier PJ, Sanyal S, Bermejo JL, Steineck G, Hemminki K, et al. Genotypes, haplotypes and diplotypes of three XPC polymorphisms in urinary-bladder cancer patients. Mutat Res. 2010;694:39-44.
47. Gangwar R, Mittal RD. Association of selected variants in genes involved in cell cycle and apoptosis with bladder cancer risk in North Indian population. DNA Cell Biol. 2010;29:349-56.
48. Yuan L, Gu X, Shao J, Wang M, Zhu Q, et al. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer. DNA Cell Biol. 2010;29:611-7.
49. Yuan L. Cyclin D1 polymorphism is associated with risk of bladder cancer in China. Nanjing: Nanjing Medical University; 2011.
50. Liu Y. Interactions of XPC gene polymorphism with prostate cancer and bladder cancer risk in China. Chongqing: Third Military Medical University; 2012.
51. Cohen LM, McCarthy DM, Brown SA, Myers MG. Negative affect combines with smoking outcome expectancies to predict smoking behavior over time. Psychol Addict Behav. 2002;16:91-7.
52. Shields PG, Harris CC. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol. 2000;18:2309-15.
53. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1513-30.
54. Zeegers MP, Tan FE, Dorant E, van Den Brandt PA. The impact of characteristics of cigarette smoking on urinary tract cancer risk: a meta-analysis of epidemiologic studies. Cancer. 2000;89:630-9.
55. Hecht SS. Tobacco smoke carcinogens and breast cancer. Environ Mol Mutagen. 2002;39:119-26.